Joel Greenblatt's SRPT Position Overview
Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 47,552 shares of Sarepta Therapeutics, Inc. (SRPT) worth $1.03 M, representing 0.00% of the portfolio. First purchased in 2017-Q3, this medium-term investment has been held for 18 quarters.
Based on 13F filings, Joel Greenblatt has maintained a strategic position in SRPT, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2025, adding 221,730 shares. Largest reduction occurred in Q1 2026, reducing 174,178 shares.
Analysis based on 13F filings available since 2013 Q2
Joel Greenblatt's Sarepta Therapeutics (SRPT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Sarepta Therapeutics (SRPT) Trades by Joel Greenblatt
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -174,178 | Reduce 78.55% | 47,552 | $21.76 |
| Q4 2025 | +221,730 | New Buy | 221,730 | $21.52 |
| Q2 2023 | -2,847 | Sold Out | 0 | $0.00 |
| Q1 2023 | -1,405 | Reduce 33.04% | 2,847 | $137.83 |
| Q4 2022 | -9,611 | Reduce 69.33% | 4,252 | $129.58 |
| Q3 2022 | +8,615 | Add 164.16% | 13,863 | $110.51 |
| Q2 2022 | -7,192 | Reduce 57.81% | 5,248 | $74.89 |
| Q1 2022 | +12,440 | New Buy | 12,440 | $78.14 |
| Q1 2020 | -1,601 | Sold Out | 0 | $0.00 |
| Q4 2019 | +1,601 | New Buy | 1,601 | $129.29 |
| Q3 2019 | -3,948 | Sold Out | 0 | $0.00 |
| Q2 2019 | -71 | Reduce 1.77% | 3,948 | $151.98 |
| Q1 2019 | -319 | Reduce 7.35% | 4,019 | $119.18 |
| Q4 2018 | -8,614 | Reduce 66.51% | 4,338 | $109.04 |
| Q3 2018 | +3,028 | Add 30.51% | 12,952 | $161.52 |
| Q2 2018 | +9,924 | New Buy | 9,924 | $132.20 |
| Q4 2017 | -9,268 | Sold Out | 0 | $0.00 |
| Q3 2017 | +9,268 | New Buy | 9,268 | $45.32 |
Joel Greenblatt's Sarepta Therapeutics Investment FAQs
Joel Greenblatt first purchased Sarepta Therapeutics, Inc. (SRPT) in Q3 2017, acquiring 9,268 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt has held Sarepta Therapeutics, Inc. (SRPT) for 18 quarters since Q3 2017.
Joel Greenblatt's largest addition to Sarepta Therapeutics, Inc. (SRPT) was in Q4 2025, adding 221,730 shares worth $4.77 M.
According to the latest 13F filing for Q1 2026, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 47,552 shares of Sarepta Therapeutics, Inc. (SRPT), valued at approximately $1.03 M.
As of the Q1 2026 filing, Sarepta Therapeutics, Inc. (SRPT) represents approximately 0.00% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings.
Joel Greenblatt's peak holding in Sarepta Therapeutics, Inc. (SRPT) was 221,730 shares, as reported at the end of Q4 2025.